LV12140B - Metode un kompozīcija bioaktīvu vielu imunoloģiskās aktivitātes noteikšanai - Google Patents

Metode un kompozīcija bioaktīvu vielu imunoloģiskās aktivitātes noteikšanai Download PDF

Info

Publication number
LV12140B
LV12140B LVP-98-125A LV980125A LV12140B LV 12140 B LV12140 B LV 12140B LV 980125 A LV980125 A LV 980125A LV 12140 B LV12140 B LV 12140B
Authority
LV
Latvia
Prior art keywords
ttp
pbl
vvith
ifn
tnf
Prior art date
Application number
LVP-98-125A
Other languages
English (en)
Latvian (lv)
Other versions
LV12140A (lv
Inventor
Anna Inglot
Zofia Blach-Olszewska
Original Assignee
Torf Establishment
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torf Establishment filed Critical Torf Establishment
Publication of LV12140A publication Critical patent/LV12140A/xx
Publication of LV12140B publication Critical patent/LV12140B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/10—Peat; Amber; Turf; Humus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
LVP-98-125A 1991-10-26 1998-05-28 Metode un kompozīcija bioaktīvu vielu imunoloģiskās aktivitātes noteikšanai LV12140B (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91118269A EP0539610A1 (en) 1991-10-26 1991-10-26 Method and composition for determining the immunological activity of solutions containing active substances

Publications (2)

Publication Number Publication Date
LV12140A LV12140A (lv) 1998-09-20
LV12140B true LV12140B (lv) 1998-12-20

Family

ID=8207282

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-125A LV12140B (lv) 1991-10-26 1998-05-28 Metode un kompozīcija bioaktīvu vielu imunoloģiskās aktivitātes noteikšanai

Country Status (23)

Country Link
US (1) US5543300A (cs)
EP (2) EP0539610A1 (cs)
JP (1) JPH07500905A (cs)
AT (1) ATE153763T1 (cs)
AU (1) AU678343B2 (cs)
BG (1) BG61705B1 (cs)
CA (1) CA2122131A1 (cs)
CZ (1) CZ100494A3 (cs)
DE (3) DE539610T1 (cs)
DK (1) DK0609255T3 (cs)
ES (1) ES2061424T3 (cs)
FI (1) FI941920A0 (cs)
GR (3) GR930300100T1 (cs)
HK (1) HK1002610A1 (cs)
HU (1) HU216863B (cs)
LV (1) LV12140B (cs)
NO (1) NO941444L (cs)
PL (1) PL170592B1 (cs)
RO (1) RO114837B1 (cs)
RU (1) RU2125727C1 (cs)
SG (1) SG72665A1 (cs)
SK (1) SK44094A3 (cs)
WO (1) WO1993008470A1 (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615470A1 (de) * 1996-04-19 1997-10-23 Heinz Beinio Körperpflegemittel und Verfahren zu seiner Herstellung
EP1115408B1 (en) * 1998-09-23 2006-01-25 Pfeinsmith Limited Oxihumic acid and its use in the treatment of various conditions
GB0101973D0 (en) * 2001-01-25 2001-03-14 Statens Seruminstitut Improved in vitro diagnostic method of detecting a cell-mediated immune response
DE60304989T2 (de) * 2003-02-18 2007-03-29 Clinique La Prairie Research S.A. Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
US7497947B2 (en) * 2004-04-14 2009-03-03 Embro Corporation Devices for water treatment
US7614340B2 (en) * 2007-02-09 2009-11-10 Honeywell International Inc. Composite piston housing for aircraft brakes
US9005449B2 (en) 2011-09-07 2015-04-14 Embro Corporation Use of moss to reduce disinfection by-products in water treated with disinfectants
US9795809B2 (en) 2013-12-23 2017-10-24 Embro Corporation Use of moss to improve dental health
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH636448A5 (en) * 1977-05-06 1983-05-31 Horst Veith Process for the determination of the effect of substances on constituents of the blood for the detection of infectious and immunological processes and composition for carrying it out
NZ214400A (en) * 1985-12-02 1989-05-29 Univ Otago Detecting infection in ruminant including conducting assay of mononuclear cell function
DE3782958D1 (de) * 1986-02-19 1993-01-21 Imreg Inc Verfahren und mittel zum pruefen eines immunsystems.
DE3779909T2 (de) * 1986-03-06 1993-01-07 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
US5096708A (en) * 1988-07-07 1992-03-17 Sven Gohla Medical preparation containing as active agent a component from thuja plants which comprises polysaccharides
ATE131859T1 (de) * 1991-03-16 1996-01-15 Torf Ets Verfahren zur kontinuierlichen extraction von torf und apparat zur durchführung dieses verfahrens

Also Published As

Publication number Publication date
EP0539610A1 (en) 1993-05-05
GR930300100T1 (cs) 1993-10-29
NO941444D0 (no) 1994-04-21
DK0609255T3 (da) 1997-12-22
BG61705B1 (bg) 1998-03-31
HU9401185D0 (en) 1994-07-28
AU2650992A (en) 1993-05-21
WO1993008470A1 (en) 1993-04-29
US5543300A (en) 1996-08-06
CZ100494A3 (en) 1994-11-16
DE609255T1 (de) 1995-06-14
JPH07500905A (ja) 1995-01-26
EP0609255B1 (en) 1997-05-28
DE69220078D1 (de) 1997-07-03
GR940300077T1 (en) 1994-11-30
EP0609255A1 (en) 1994-08-10
SK44094A3 (en) 1995-03-08
LV12140A (lv) 1998-09-20
ATE153763T1 (de) 1997-06-15
HU216863B (hu) 1999-09-28
ES2061424T3 (es) 1997-10-01
DE69220078T2 (de) 1997-12-04
BG98720A (bg) 1995-07-28
RU2125727C1 (ru) 1999-01-27
RU94022481A (ru) 1996-09-27
HK1002610A1 (en) 1998-09-04
CA2122131A1 (en) 1993-04-29
AU678343B2 (en) 1997-05-29
NO941444L (no) 1994-06-16
FI941920A (fi) 1994-04-25
DE539610T1 (de) 1993-12-16
PL170592B1 (en) 1997-01-31
HUT69990A (en) 1995-09-28
SG72665A1 (en) 2000-05-23
GR3024457T3 (en) 1997-11-28
ES2061424T1 (es) 1994-12-16
FI941920A0 (fi) 1994-04-25
RO114837B1 (ro) 1999-07-30

Similar Documents

Publication Publication Date Title
Glaser et al. Stress depresses interferon production by leukocytes concomitant with a decrease in natural killer cell activity.
Fong et al. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.
Weigent et al. Interleukin 2 enhances natural killer cell activity through induction of gamma interferon
Rubin et al. Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents.
Valle et al. Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons
Touil-Boukoffa et al. Production of nitric oxide (NO) in human hydatidosis: relationship between nitrite production and interferon-γ levels
Friedman et al. Stimulation of interferon production in human lymphocytes by mitogens
Brown et al. Functional and phenotypic characterization of WC1+ γ/δ T cells isolated from Babesia bovis-stimulated T cell lines
Laszlo et al. Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer
EP0609255B1 (en) Method and composition for determining the immunological activity of bioactive substances
CEDERBLAD et al. Infrequent but efficient interferon-α-producing human mononuclear leukocytes induced by herpes simplex virus in vitro studied by immuno-plaque and limiting dilution assays
TOUIL-BOUKOFFA et al. Relationship among circulating interferon, tumor necrosis factor-α, and interleukin-6 and serologic reaction against parasitic antigen in human hydatidosis
Dimier et al. Inhibition of Eimeria tenella development in vitro mediated by chicken macrophages and fibroblasts treated with chicken cell supernatants with IFN-γ activity
Hoover et al. Human monocyte activation for cytotoxicity against intracellular Leishmania donovani amastigotes: induction of microbicidal activity by interferon-γ
Preble et al. ROLE OF INTERFERON IN AIDS a
Verhaegen-Lewalle et al. 2-5A synthetase activity induced by interferon α, β, and γ in human cell lines differing in their sensitivity to the anticellular and antiviral activities of these interferons
Jonsson et al. Elevated serum interferon levels in patients with Bell's palsy
US4499093A (en) Interferon induction method
Turco et al. Comparison of the properties of antirickettsial activity and interferon in mouse lymphokines
Gastl et al. Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing
Vervliet et al. Interferon production by cultured peripheral leucocytes of MS patients.
Fischer et al. Spontaneous production of interferon-γ and acid-labile interferon-α by subpopulations of human mononuclear cells
Funa et al. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon.
Ingimarsson et al. Immune Reactions and Long‐Term Therapy with Human Leukocyte Interferon
US5565549A (en) CD8+ cell antiviral factor